Cactus Life Sciences
Fishawack Health Founder's Deep History in Healthcare Communications Blends Nicely with Global Scientific Communications Agency's Upcoming Buy-and-Build Strategy
PRINCETON, NJ / ACCESSWIRE / April 16, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that Oliver Dennis has joined them as Chairman, to work alongside Co-founder, Anurag Goel.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.Cactus Life Sciences, headquartered in Princeton, New Jersey was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. "We're delighted to have someone with Oliver's experience of growing businesses join the team," said Anurag. "Cactus Life Sciences is about to undertake an exciting buy and build strategy. And Oliver is the perfect addition with his deep history in healthcare communications having founded Fishawack Health® (now Avalere®)."
During Oliver's tenure at Fishawack, he acquired 17 businesses over 13 years including medical communications and branding agencies, as well as strategic healthcare consultancies and market access and HEOR advisory firms. He led 4 management buy outs to take the business from a start-up to over 1400 people across 22 offices, spanning San Diego to Singapore. Oliver will specifically help shape the future vision for Cactus Life Sciences as the healthcare communications agency partner of the future (strategic, agile, tech-enabled, and outcomes focused) to take on traditional agencies which have lost agility and identity in the pursuit of maximizing profit. He will play an active role in driving the inorganic growth strategy for the business, while pursuing his passion for bringing people together from different businesses and disciplines to collaborate on better outcomes for clients, patients, and our people.
"I've been following Cactus over the last 10 years and they're a great organization. I'm excited to be joining them. They've grown consistently and they have the ambition to become the next generation challenger brand to the traditional players in the market," said Oliver. "This is an opportunity to do something with a greater focus on solving client challenges, improving health outcomes, and nurturing our people."
"Too many companies get to a size where they lose their sense of purpose, values, and forget about individuality. As we work toward transforming Cactus Life Sciences into an agency of the future, we want to ensure that we do so while ensuring that patients and our people are at the core of everything we do," said Elvira D'souza, President of Cactus Life Sciences.
About Cactus Life Sciences (cactuslifesciences.com) Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world─with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes. CACTUS has offices in Princeton, London, Aarhus, Singapore, Beijing, Shanghai, Seoul, Tokyo, and Mumbai.
Contact Information:
Laura Perry
Vice President of Strategy & Marketing
laura.perry@cactusglobal.com
7327121005
SOURCE: Cactus Life Sciences
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom